Authors: F. Holm; M. Aschermann 1 Authors‘ workplace: Kardiologické oddělení, Krajská nemocnice Liberec 1II. interní klinika 1. LF UK a VFN, Praha Published in: Čas. Lék. čes. 2003; : 456-459 Category:
Acute coronary syndromes (ACS) are caused by neoinclusive thrombosis of the coronary artery. Arterial atherothrombosisusually results from a cracked atheroma plate and includes platelet and plasmatic component ofcoagulation. The aim of pharmacological treatment is to influence activated platelets and plasma procoagulantactivity. Several clinical studies have demonstrated the benefits of antithrombotic treatment by acetylsalicylic acid,clopidogrel and by blockers of platelet receptors IIb/IIIa. In ACS anticoagulant therapy the non-fractionated heparinare replace ed by low-molecular heparins. The new standard in ACS therapy should become a combination of theacetylsalicylic acid, enoxaparine and clopidogrel. Blockers of platelet receptors IIb/IIIa should be given namely topatients indicated for the early invasive treatment.
Key words: acute coronary syndrome, pharmacotherapy.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
